Xynomic Pharma Has Acquired Worldwide Rights of Abexinostat

CHEYENNE, Wyoming, Feb. 24, 2017 /PRNewswire/ -- Xynomic Pharmaceuticals, Inc., an oncology drug research and development company, today announced that it has acquired exclusive worldwide rights to develop, manufacture and commercialize Abexinostat, a potentially best-in-class innovative HDAC inhibitor targeting hematological and solid tumors.

To date a total of 14 Phase 1 and 2 clinical trials of Abexinostat in US, EU and Asia have already been completed, demonstrating that Abexinostat is clinically active in multiple tumor settings with a more favorable safety profile among HDAC products.  Xynomic aims to initiate Phase 3 registrational trials worldwide in Q3'2017.

"We are honored and excited to forge this landmark agreement.  We will deploy necessary resources and closely work with KOLs to expeditiously bring this innovative drug to the market to address unmet medical needs," said Mr. Y. Mark Xu, Co-Founder, Chairman and CEO of Xynomic.

About Xynomic Pharmaceuticals, Inc.

A US company founded by seasoned biopharmaceutical executives and successful entrepreneurs, Xynomic focuses on in-licensing, developing and commercializing oncology drug candidates in US, Asia, EU and rest of the world.  The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck and Roche) in R&D roles.  The founders also had successful entrepreneurial experiences including founding, building and exiting successful US-China biopharmaceutical companies.

SOURCE Xynomic Pharmaceuticals, Inc.